HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9025 | Ramucirumab | Cyramza | 5 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2014 | Oct 1, 2014 | Dec 31, 2015 | No Longer Used | |
J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
NA | Regorafenib | Stivarga | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl | Yes | 2012 | In Use | |||
NA | Relugolix | Orgovyx | 120mg | Hormonal Therapy | Androgen Receptor Inhibitor | GnRH Receptor Antagonist | Yes | 2020 | In Use | |||
J9345 | Retifanlimab-dlwr | Zynyz | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2023 | Aug 28, 2023 | In Use | ||
NA | Ribociclib and letrozole | Kisqali Femara Co-pack | 200 mg/ 2.5 mg | Chemotherapy, Hormonal Therapy | Cyclin dependent kinase inhibitor/ aromatase inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Ribociclib | Kisqali | 200 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
J9311 | Rituximab and Hyaluronidase | Rituxan Hycela | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2017 | Jan 1, 2019 | In Use | ||
J9310 | Rituximab | Rituxan | 100 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 1997 | Jan 1, 1999 | In Use | ||
Q5115 | Rituximab-abbs | Truxima | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2018 | Jul 1, 2019 | In Use | ||
Q5123 | Rituximab-arrx | Riabni | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2021 | Jul 23, 2021 | In Use | ||
Q5119 | Rituximab-pvvr | Ruxience | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2019 | Jul 1, 2020 | In Use | ||
J8670 | Rolapitant | Varubi | 1 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2015 | Jan 1, 2017 | In Use | ||
J9315 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | Jan 1, 2011 | Sep 27, 2021 | No Longer Used | |
C9065 | Romidepsin | Romidepsin | 1mg | Chemotherapy | Enzyme Inhibetor | HDAC | No | 2020 | Jan 1, 2021 | Sep 27, 2021 | No Longer Used | |
C9265 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | Jul 1, 2010 | Dec 31, 2010 | No Longer Used | |
J9319 | Romidepsin, lyophilized | Istodax | 0.1mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2010 | Sep 27, 2021 | In Use | ||
J9318 | Romidepsin, non-lyophilized | Romidepsin | 0.1mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2020 | Sep 27, 2021 | In Use | ||
NA | Rucaparib | Rubraca | 300 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Rucaparib | Rubraca | 250 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Rucaparib | Rubraca | 200 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.